Bristol Myers Q2 GAAP EPS rises to 1.62; revenue increases 5.7% to 13 billion - BMY News | RalliesBristol Myers Q2 GAAP EPS rises to 1.62; revenue increases 5.7% to 13 billion
B
BMY• Outlook
- Raised 2026 non-GAAP revenue outlook to about USD 49-50 billion; lifted non-GAAP EPS view to USD 6.75-7.
Quarterly results
- Bristol-Myers Squibb Q2 2026 total revenues rose 5.7% to USD 13 billion; GAAP diluted EPS climbed to USD 1.62 from USD 0.64.
- Non-GAAP diluted EPS increased 39.7% to USD 2.04; gross margin slipped 1.2 percentage points to 71.3%.
- Growth Portfolio revenue rose 15% to USD 7.6 billion; Opdivo net sales fell 3% to USD 2.49 billion.
- Eliquis net sales rose 22% to USD 4.48 billion; Camzyos more than doubled to USD 416 million.
•
